The DOI matches its Crossref record; 87 of the 88 references it cites were found in a registry or an index.
Trisomy 21 consistently activates the interferon response
Open accessAbstract
Although it is clear that trisomy 21 causes Down syndrome, the molecular events acting downstream of the trisomy remain ill defined. Using complementary genomics analyses, we identified the interferon pathway as the major signaling cascade consistently activated by trisomy 21 in human cells. Transcriptome analysis revealed that trisomy 21 activates the interferon transcriptional response in fibroblast and lymphoblastoid cell lines, as well as circulating monocytes and T cells. Trisomy 21 cells show increased induction of interferon-stimulated genes and decreased expression of ribosomal proteins and translation factors. An shRNA screen determined that the interferon-activated kinases JAK1 and TYK2 suppress proliferation of trisomy 21 fibroblasts, and this defect is rescued by pharmacological JAK inhibition. Therefore, we propose that interferon activation, likely via increased gene dosage of the four interferon receptors encoded on chromosome 21, contributes to many of the clinical impacts of trisomy 21, and that interferon antagonists could have therapeutic benefits.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures





















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, both individuals with DS and mouse models of DS experience constitutive hyperactivation of interferon (IFN) signaling with signs of chronic inflammation and immune dysregulation,30,31,32,33,34,35,36,37,38,39,40 that could exacerbate the neuroinflammatory response.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“we reported the results of transcriptome analyses of four different cell types obtained from people with and without T21, which demonstrated that T21 causes widespread alterations in gene expression across the genome”
From Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation (2017) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“including, most prominently, consistent activation of the interferon transcriptional response17”
From Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation (2017) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“However, unbiased analyses using omics technology have recently revealed that T21 impacts gene expression across the genome39,74,143,156–159.”
From Consequences of trisomy 21 for brain development in Down syndrome (2024) · cites this paper as [159]
The cited source says what the claim attributes to it.
In the citing paper
“people with DS present an increased IFN signaling likely driven by triplication of four of the six IFN receptors encoded on HSA21,36 rather than by massive elevation of the IFN ligands themselves as seen in interferonopathies,80 and this has been associated with chronic immune dysregulation.”
From Interferon signaling modulates Down syndrome-associated Alzheimer’s disease pathology in a mouse model (2025) · cites this paper as [36]
The cited source says what the claim attributes to it.
In the citing paper
“Accumulating evidence supports the classification of DS as a multisystem interferonopathy (62, 63, 75).”
From Molecular and cellular processes disrupted in the early postnatal Down syndrome prefrontal cortex (2026) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“Given the dysregulated interferon signaling observed across multiple Ts21 organ systems (62, 63), we characterized the expression of interferon receptors, along with downstream interferon response genes.”
From Molecular and cellular processes disrupted in the early postnatal Down syndrome prefrontal cortex (2026) · cites this paper as [62]
The cited source says what the claim attributes to it.
In the citing paper
“our RNA-Seq analyses, combined with previously published RNA-Seq data (Letourneau et al., 2014;Sullivan et al., 2016), showed transcript levels for the analyzed acid hydrolases to be comparable in 2N and DS fibroblasts”
From Lysosomal Dysfunction in Down Syndrome Is APP-Dependent and Mediated by APP-βCTF (C99) (2019) · cites this paper as Sullivan et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Causal analysis approaches in Ingenuity Pathway Analysis
Krämer, A., Green, J., Pollard, J., & Tugendreich, S. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt703 · Cited by 5,724
RSeQC: quality control of RNA-seq experiments
Wang, L., Wang, S., & Li, W. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts356 · Cited by 2,753
A diverse range of gene products are effectors of the type I interferon antiviral response
Schoggins, J. W., Wilson, S. J., Panis, M., Murphy, M. Y., Jones, C. T., Bieniasz, P. D., & Rice, C. M. (2011) · Nature · doi:10.1038/nature09907 · Cited by 2,412
WebGestalt: an integrated system for exploring gene sets in various biological contexts
Zhang, B., Kirov, S. A., & Snoddy, J. R. (2005) · Nucleic Acids Research · doi:10.1093/nar/gki475 · Cited by 1,803
WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): update 2013
Wang, J., Duncan, D. T., Shi, Z., & Zhang, B. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt439 · Cited by 1,512
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Pathway Commons, a web resource for biological pathway data
Cerami, E. G., Gross, B. E., Demir, E., Rodchenkov, I., Babur, O., Anwar, N., Schultz, N., Bader, G. D., & Sander, C. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq1039 · Cited by 1,101
Association and Activation of Jak-Tyk Kinases by CNTF-LIF-OSM-IL-6 β Receptor Components
Stahl, N., Boulton, T. G., Farruggella, T., Ip, N. Y., Davis, S., Witthuhn, B. A., Quelle, F. W., Silvennoinen, O., Barbieri, G., Pellegrini, S., et al. (1994) · Science · doi:10.1126/science.8272873 · Cited by 979
MYC as a regulator of ribosome biogenesis and protein synthesis
van Riggelen, J., Yetil, A., & Felsher, D. W. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2819 · Cited by 956
Aicardi–Goutières syndrome and the type I interferonopathies
Crow, Y. J., & Manel, N. (2015) · Nature Reviews Immunology · doi:10.1038/nri3850 · Cited by 925
Quintás-Cardama, A., Vaddi, K., Liu, P., Manshouri, T., Li, J., Scherle, P. A., Caulder, E., Wen, X., Li, Y., Waeltz, P., et al. (2010) · Blood · doi:10.1182/blood-2009-04-214957 · Cited by 843
Shuai, K., Horvath, C. M., Huang, L. H. T., Qureshi, S. A., Cowburn, D., & Darnell, J. E. (1994) · Cell · doi:10.1016/0092-8674(94)90357-3 · Cited by 807
The Scanning Mechanism of Eukaryotic Translation Initiation
Hinnebusch, A. G. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060713-035802 · Cited by 798
The protein tyrosine kinase JAK1 complements defects in interferon-α/β and -γ signal transduction
Müller, M., Briscoe, J., Laxton, C., Guschin, D., Ziemiecki, A., Silvennoinen, O., Harpur, A., Barbieri, G., Witthuhn, B., Schindler, C., et al. (1993) · Nature · doi:10.1038/366129a0 · Cited by 680
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562
c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription
Arabi, A., Wu, S., Ridderstråle, K., Bierhoff, H., Shiue, C.-N., Fátyol, K., Fahlén, S., Hydbring, P., Söderberg, O., Grummt, I., et al. (2005) · Nature Cell Biology · doi:10.1038/ncb1225 · Cited by 507
Wichers, M. C., Koek, G. H., Robaeys, G., Verkerk, R., Scharpé, S., & Maes, M. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001600 · Cited by 445
Boon, K., Caron, H. N., van Asperen, R., Valentijn, L. J., Hermus, M.-C., Sluis, P. V., Roobeek, I., Weis, I., Voûte, P. A., Schwab, M., et al. (2001) · The EMBO Journal · doi:10.1093/emboj/20.6.1383 · Cited by 439
Spastic diplegia as a complication of interferon Alfa-2a treatment of hemangiomas of infancy
Barlow, C. F., Priebe, C. J., Mulliken, J. B., Barnes, P. D., Donald, D. M., Folkman, J., & Ezekowitz, R. A. B. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70034-4 · Cited by 436
HIF1A Employs CDK8-Mediator to Stimulate RNAPII Elongation in Response to Hypoxia
Galbraith, M. D., Allen, M. A., Bensard, C., Wang, X., Schwinn, M. K., Qin, B., Long, H. W., Daniels, D. L., Hahn, W. C., Dowell, R. D., et al. (2013) · Cell · doi:10.1016/j.cell.2013.04.048 · Cited by 379
Self-citationCDK8 is a positive regulator of transcriptional elongation within the serum response network
Donner, A. J., Ebmeier, C. C., Taatjes, D. J., & Espinosa, J. M. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1752 · Cited by 368
Self-citationPerluigi, M., Di Domenico, F., & Butterfield, D. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.014 · Cited by 339
Domains of genome-wide gene expression dysregulation in Down’s syndrome
Letourneau, A., Santoni, F. A., Bonilla, X., Sailani, M. R., Gonzalez, D., Kind, J., Chevalier, C., Thurman, R., Sandstrom, R. S., Hibaoui, Y., et al. (2014) · Nature · doi:10.1038/nature13200 · Cited by 319
Wichers, M., & Maes, M. H. J. (2004) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0402 · Cited by 294
Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy
Hathout, Y., Brody, E. N., Clemens, P. R., Cripe, L. H., DeLisle, R. K., Furlong, P., Gordish‐Dressman, H., Hache, L. P., Henricson, E., Hoffman, E. P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507719112 · Cited by 289
Keystone, E. C., Taylor, P. C., Drescher, E., Schlichting, D. E., Beattie, S. D., Berclaz, P., Lee, C. H., Fidelus-Gort, R., Luchi, M., Rooney, T. P., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206478 · Cited by 282
Advances in human proteomics at high scale with the SOMAscan proteomics platform
Gold, L., Walker, J. J., Wilcox, S. K., & Williams, S. A. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.11.016 · Cited by 268
Tinkering with Translation: Protein Synthesis in Virus-Infected CellsPreprint
Walsh, D., Mathews, M. B., & Mohr, I. (2012) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012351 · Cited by 259
Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
Jabbari, A., Dai, Z., Xing, L., Cerise, J. E., Ramot, Y., Berkun, Y., Sanchez, G. A. M., Goldbach‐Mansky, R. T., Christiano, A. M., Clynes, R., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.02.015 · Cited by 235
Shi, J. G., Chen, X., Lee, F., Emm, T. A., Scherle, P., Lo, Y. Y. C., Punwani, N. G., Williams, W. V., & Yeleswaram, S. (2014) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.354 · Cited by 224
Li, Z., Yu, T., Morishima, M., Pao, A., LaDuca, J., Conroy, J., Nowak, N., Matsui, S.-I., Shiraishi, I., & Yu, Y. E. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm086 · Cited by 218
Low risk of solid tumors in persons with Down syndrome
Hasle, H., Friedman, J. M., Olsen, J. H., & Rasmussen, S. A. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.23 · Cited by 188
Kim, S., Li, Q., Dang, C. V., & Lee, L. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.200372597 · Cited by 187
White-to-brown metabolic conversion of human adipocytes by JAK inhibition
Moisan, A., Lee, Y., Zhang, J. D., Hudak, C. S. S., Meyer, C. A., Prummer, M., Zoffmann, S., Truong, H., Ebeling, M., Kiialainen, A., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3075 · Cited by 182
Malinge, S., Bliss‐Moreau, M., Kirsammer, G. T., Diebold, L. P., Chlon, T. M., Gurbuxani, S. K., & Crispino, J. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60455 · Cited by 180
Long-Term Outcome of Treatment with Ruxolitinib in Myelofibrosis
Tefferi, A., Litzow, M. R., & Pardanani, A. D. (2011) · New England Journal of Medicine · doi:10.1056/nejmc1109555 · Cited by 161
Risk of Major Cardiovascular Events in People with Down Syndrome
Sobey, C. G., Judkins, C. P., Sundararajan, V., Phan, T. G., Drummond, G. R., & Srikanth, V. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0137093 · Cited by 156
Dissecting Interferon-Induced Transcriptional Programs in Human Peripheral Blood Cells
Waddell, S. J., Popper, S. J., Rubins, K., Griffiths, M. J., Brown, P. O., Levin, M., & Relman, D. A. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009753 · Cited by 148
Alexander, M., Petri, H., Ding, Y., Wandel, C., Khwaja, O., & Foskett, N. (2015) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12868 · Cited by 148
Human Chromosome 21 Dosage: Effect on the Expression of the Interferon Induced Antiviral State
Tan, Y., Schneider, E. L., Tischfield, J. A., Epstein, C. J., & Ruddle, F. H. (1974) · Science · doi:10.1126/science.186.4158.61 · Cited by 144
Hedgehog Agonist Therapy Corrects Structural and Cognitive Deficits in a Down Syndrome Mouse Model
Das, I., Park, J. M., Shin, J. H., Jeon, S. K., Lorenzi, H., Linden, D. J., Worley, P. F., & Reeves, R. H. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005983 · Cited by 141
Taylor, M. W., Tsukahara, T., Brodsky, L., Schaley, J. E., Sanda, C., Stephens, M. J., McClintick, J. N., Edenberg, H. J., Li, L., Tavis, J. E., et al. (2007) · Journal of Virology · doi:10.1128/jvi.02640-06 · Cited by 122
Haematopoietic development and leukaemia in D own syndrome
Roberts, I. A. G., & Izraeli, S. (2014) · British Journal of Haematology · doi:10.1111/bjh.13096 · Cited by 111
Interferons and cerebral palsy
Grether, J. K., Nelson, K. B., Dambrosia, J. M., & Phillips, T. M. (1999) · The Journal of Pediatrics · doi:10.1016/s0022-3476(99)70458-0 · Cited by 107
Padron, E., Dezern, A. E., Andrade‐Campos, M., Vaddi, K., Scherle, P., Zhang, Q., Ma, Y., Balasis, M. E., Tinsley, S., Ramadan, H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2781 · Cited by 102
Lindvall, C. J., Hou, M., Komurasaki, T., Zheng, C., Arsenian‐Henriksson, M., Sedivy, J. M., Björkholm, M., Teh, B. T., Nordenskjöld, M., & Xu, D. (2003) · PubMed · Cited by 99
Immunopathology of the human pancreas in type-I diabetes
Richardson, S. J., O’Connell, A., Bone, A. J., Morgan, N. G., & Foulis, A. K. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-010-0205-0 · Cited by 88
Yao, Y., Higgs, B. W., Richman, L. K., White, B., & Jallal, B. (2010) · Arthritis Research & Therapy · doi:10.1186/ar2887 · Cited by 82
Validation of a blood protein signature for non-small cell lung cancer
Mehan, M. R., Williams, S. A., Siegfried, J. M., Bigbee, W. L., Weissfeld, J. L., Wilson, D. O., Pass, H. I., Rom, W. N., Muley, T., Meister, M. A., et al. (2014) · Clinical Proteomics · doi:10.1186/1559-0275-11-32 · Cited by 81
Detection of mycoplasma in leukemia–lymphoma cell lines using polymerase chain reaction
Uphoff, C., & Drexler, H. (2002) · Leukemia · doi:10.1038/sj.leu.2402365 · Cited by 79
Choi, H., Kim, S., Fermin, D., Tsou, C., & Nesvizhskii, A. I. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.07.036 · Cited by 77
Simmons, D. S., Fleming, C., Voyle, J., Fou, F., Feo, S., & Gatland, B. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199802)15:2 · Cited by 76
A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials
de Sola, S., The TESDAD Study Group, de la Torre, R., Sánchez‐Benavides, G., Benejam, B., Cuenca‐Royo, A., Soriano, L. D. H., RodrÃguez, J., Catuara‐Solarz, S., Sánchez-Gutiérrez, J., et al. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00708 · Cited by 75
Tisserand, J., Khetchoumian, K., Thibault-Carpentier, C., Dembélé, D., Chambon, P., & Losson, R. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.225680 · Cited by 73
Ruxolitinib: A Review of Its Use in Patients with Myelofibrosis
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0351-8 · Cited by 71
Massive-Scale RNA-Seq Analysis of Non Ribosomal Transcriptome in Human Trisomy 21
Costa, V., Angelini, C., D’Apice, L., Mutarelli, M., Casamassimi, A., Sommese, L., Gallo, M. A., Aprile, M., Esposito, R., Leone, L., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018493 · Cited by 70
mTOR Hyperactivation in Down Syndrome Hippocampus Appears Early During Development
Iyer, A. M., van Scheppingen, J., Milenkovic, I., Anink, J. J., Adle-Biassette, H., Kovacs, G. G., & Aronica, E. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000083 · Cited by 69
Presence of human chromosome 21 alone is sufficient for hybrid cell sensitivity to human interferon
Slate, D. L., Shulman, L. M., Lawrence, J. B., Revel, M., & Ruddle, F. H. (1978) · Journal of Virology · doi:10.1128/jvi.25.1.319-325.1978 · Cited by 69
Ling, K., Hewitt, C., Tan, K.-L., Cheah, P.-S., Vidyadaran, S., Lai, M. I., Lee, H.-C., Simpson, K., Hyde, L., Pritchard, M. A., et al. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-624 · Cited by 68
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53
Sullivan, K. D., Padilla-Just, N., Henry, R. E., Porter, C. C., Kim, J., Tentler, J. J., Eckhardt, S. G., Tan, A. C., DeGregori, J., & Espinosa, J. M. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.965 · Cited by 67
Self-citationInterferon alpha-2a therapy in haemangiomas of infancy: spastic diplegia as a severe complication
Wörle, H., Maaß, E., Köhler, B., & Treuner, J. (1999) · European Journal of Pediatrics · doi:10.1007/s004310051089 · Cited by 66
Type I interferon dysregulation and neurological disease
McGlasson, S. L., Jury, A., Jackson, A. P., & Hunt, D. P. J. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.143 · Cited by 59
Malinge, S., Chlon, T. M., Doré, L. C., Ketterling, R. P., Tallman, M. S., Paietta, E. M., Gamis, A. S., Taub, J. W., Chou, S. T., Weiss, M. J., et al. (2013) · Blood · doi:10.1182/blood-2013-05-503011 · Cited by 55
Lee, H.-C., Tan, K.-L., Cheah, P.-S., & Ling, K. (2016) · Neural Plasticity · doi:10.1155/2016/7434191 · Cited by 53
Maroun, L. E., Heffernan, T., & Hallam, D. M. (2000) · Journal of Interferon & Cytokine Research · doi:10.1089/107999000312612 · Cited by 44
Troca-Marín, J. A., Casañas, J. J., Benito, I., & Montesinos, M. L. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660184 · Cited by 43
Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain
Ahmed, M. M., Dhanasekaran, A. R., Tong, S., Wiseman, F. K., Fisher, E., Tybulewicz, V. L. J., & Gardiner, K. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt017 · Cited by 43
Sun, L., Tian, Z., & Wang, J. (2009) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2009.09.016 · Cited by 38
Spaner, D., Wang, G., McCaw, L., Li, Y., Disperati, P., Cussen, M., & Shi, Y. (2016) · Haematologica · doi:10.3324/haematol.2015.135418 · Cited by 34
AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL
Stankiewicz, M. J., & Crispino, J. D. (2013) · Leukemia · doi:10.1038/leu.2013.33 · Cited by 30
Tanaka, M. H., Giro, E. M. A., Cavalcante, L. B., Pires, J. R., Apponi, L. H., Valentini, S. R., Spolidório, D. M. P., Capela, M. V., Rossa, C., & Scarel‐Caminaga, R. M. (2012) · Cytokine · doi:10.1016/j.cyto.2012.08.020 · Cited by 28
Ruxolitinib: A Review in Polycythaemia Vera
McKeage, K. (2015) · Drugs · doi:10.1007/s40265-015-0470-2 · Cited by 28
INHIBITION OF PROTEIN SYNTHESIS IN NONINFECTED L CELLS BY PARTIALLY PURIFIED INTERFERON PREPARATIONS
Johnson, T. C., Lerner, M. P., & Lancz, G. J. (1968) · The Journal of Cell Biology · doi:10.1083/jcb.36.3.617 · Cited by 27
Iwamoto, T., Yamada, A., Yuasa, K., Fukumoto, E., Nakamura, T., Fujiwara, T., & Fukumoto, S. (2009) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2009.07.009 · Cited by 23
Anti‐interferon immunoglobulins can improve the trisomy 16 mouse phenotype
Maroun, L. E. (1995) · Teratology · doi:10.1002/tera.1420510509 · Cited by 21
Expression Signature as a Biomarker for Prenatal Diagnosis of Trisomy 21
Volk, M., Maver, A., Lovrečić, L., Juvan, P., & Peterlin, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0074184 · Cited by 19
Questioned validity of Gene Expression Dysregulated Domains in Down's Syndrome
Do, L. H., Mobley, W. C., & Singhal, N. (2015) · F1000Research · doi:10.12688/f1000research.6735.1 · Cited by 18
Gupta, R., Kim, S., & Taylor, M. W. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-54 · Cited by 17
AnaLysis of Expression on human chromosome 21, ALE-HSA21: a pilot integrated web resource
Scarpato, M., Esposito, R., Evangelista, D., Aprile, M., Ambrosio, M. R., Angelini, C., Ciccodicola, A., & Costa, V. (2014) · Database · doi:10.1093/database/bau009 · Cited by 15
Solid Malignancies in Individuals With Down Syndrome: A Case Presentation and Literature Review
Bratman, S. V., Horst, K. C., Carlson, R. W., & Kapp, D. S. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0153 · Cited by 14
Huang, C. Y., Liu, L., Li, Z., Wang, P., Ni, L., Song, L., Xu, D., & Song, T. (2008) · Cell Biology International · doi:10.1016/j.cellbi.2008.04.019 · Cited by 11
Interferon-mediated effect on ribosomal RNA metabolism
Maroun, L. E. (1978) · Biochimica et Biophysica Acta (BBA) - Nucleic Acids and Protein Synthesis · doi:10.1016/0005-2787(78)90038-2 · Cited by 10
The Genetics of the Antiviral State in Human Cells
Tan, Y., Tischfield, J. A., & Ruddle, F. H. (2008) · Cytogenetics and Cell Genetics · doi:10.1159/000130262 · Cited by 3
Cited by
Sorted by citations
Antonarakis, S. E., Skotko, B. G., Rafii, M. S., Strydom, A., Pape, S. E., Bianchi, D. W., Sherman, S. L., & Reeves, R. H. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0143-7 · Cited by 964
Interferons and Proinflammatory Cytokines in Pregnancy and Fetal Development
Yockey, L. J., & Iwasaki, A. (2018) · Immunity · doi:10.1016/j.immuni.2018.07.017 · Cited by 588
Watanabe, M., Buth, J. E., Vishlaghi, N., de la Torre-Ubieta, L., Taxidis, J., Khakh, B. S., Coppola, G., Pearson, C. A., Yamauchi, K., Gong, D., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.047 · Cited by 401
Santaguida, S., Richardson, A., Iyer, D., M’Saad, O., Zasadil, L. M., Knouse, K. A., Wong, Y. L., Rhind, N., Desai, A. B., & Amon, A. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.05.022 · Cited by 367
Bradley, K. C., Finsterbusch, K., Schnepf, D., Crotta, S., Llorian, M., Davidson, S., Fuchs, S. Y., Staeheli, P., & Wack, A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.105 · Cited by 313
Metadata
- Authors
- Sullivan, K. D., Lewis, H. C., Hill, A. A., Pandey, A., Jackson, L. P., Cabral, J. M., Smith, K. P., Liggett, L. A., Gomez, E. B., Galbraith, M. D., DeGregori, J., & Espinosa, J. M.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Colorado Anschutz (US)
- Linda Crnic Institute for Down Syndrome, University of Colorado School of Medicine, Aurora, United States
- Corresponding author
- Sullivan, Kelly D
- ORCID
- Venue
- eLife
- Publisher
- eLife Sciences Publications, Ltd
- Published
- 2016-07-29
- Volume
- 5
- ISSN
- 2050-084X (ISSN-L)
- PMC
- PMC5012864
- OpenAlex
- W2487528628
- Cited by
- 362
- References
- 88
- Citations by year
- 2026: 50 · 2025: 41 · 2024: 58 · 2023: 40 · 2022: 40 · 2021: 42 · 2020: 36 · 2019: 21 · 2018: 14 · 2017: 16 · 2016: 3
- FWCI
- 17.85
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- eLife (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- University of Colorado (Linda Crnic Institute for Down Syndrome)
- Howard Hughes Medical Institute
- National Institutes of Health (R01CA117907, P30CA046934-27)
- National Science Foundation (MCB-1243522)
- Anna and John J. Sie Foundation
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Down syndrome and intellectual disability research
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
- Keywords
- Down syndrome, interferon signaling, interferon-stimulated genes, gene dosage, interferon receptor, JAK1, TYK2, ribosomal proteins, translation (biology), cell proliferation, shRNA screen, JAK inhibition, transcriptome
- MeSH terms
- Cells, Cultured, Down Syndrome, Fibroblasts, Humans, Immunity, Innate, Interferons, Monocytes, T-Lymphocytes, Gene Expression Profiling
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review